Clinical implant dentistry and related research · 2026
The Survival of Dental Implants in Post-Menopausal Women Receiving Denosumab: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hwang Junghye, Yoon Youngjae, Byun Garam, Choi Byung-Joon, Ohe Joo-Young, Lee Baek-Soo, Jung Junho
Аннотация
OBJECTIVES: This study aimed to evaluate the effects of anti-resorptive drugs (ARD), including denosumab, on dental implant survival in post-menopausal women with osteoporosis, compared with those receiving non-ARD, and to identify risk factors associated with ARD that may influence implant outcomes.
MATERIAL AND METHODS: This retrospective cohort study examined 1694 implants placed in 806 women aged 55 years or older with at least of follow-up of 12 months. Implants were categorized according to exposure to anti-resorptive drugs (ARD), including bisphosphonates or denosumab, or assignment to a non-ARD control group. The assessed variables included demographic, ARD-related, implant/prosthesis-related factors, and marginal bone loss. Propensity score matching was used to balance group characteristics. Statistical analyses included Firth logistic regression with patient-level clustering and a linear mixed model for longitudinal bone changes. Kaplan-Meier curves were illustrated to describe implant survival trends among the groups.
RESULTS: Implant survival rates were 99.13% (bisphosphonates), 98.08% (denosumab), and 98.24% (control), with no significant differences in implant failure or marginal bone loss between the groups. However, diabetes mellitus, alcohol consumption, and overdenture prosthesis were associated with a significantly increased risk of implant failure.
CONCLUSION: Implant-based prosthetic rehabilitation is also feasible in post-menopausal women receiving ARD for osteoporosis. Although the implant survival rate was comparable to non-ARD users, caution is advised for patients on high doses of ARD or undergoing long-term therapy due to their pharmacological effects compromising bone metabolism. Additionally, the risk of failure associated with invasive procedures needs to be further evaluated.
MATERIAL AND METHODS: This retrospective cohort study examined 1694 implants placed in 806 women aged 55 years or older with at least of follow-up of 12 months. Implants were categorized according to exposure to anti-resorptive drugs (ARD), including bisphosphonates or denosumab, or assignment to a non-ARD control group. The assessed variables included demographic, ARD-related, implant/prosthesis-related factors, and marginal bone loss. Propensity score matching was used to balance group characteristics. Statistical analyses included Firth logistic regression with patient-level clustering and a linear mixed model for longitudinal bone changes. Kaplan-Meier curves were illustrated to describe implant survival trends among the groups.
RESULTS: Implant survival rates were 99.13% (bisphosphonates), 98.08% (denosumab), and 98.24% (control), with no significant differences in implant failure or marginal bone loss between the groups. However, diabetes mellitus, alcohol consumption, and overdenture prosthesis were associated with a significantly increased risk of implant failure.
CONCLUSION: Implant-based prosthetic rehabilitation is also feasible in post-menopausal women receiving ARD for osteoporosis. Although the implant survival rate was comparable to non-ARD users, caution is advised for patients on high doses of ARD or undergoing long-term therapy due to their pharmacological effects compromising bone metabolism. Additionally, the risk of failure associated with invasive procedures needs to be further evaluated.